CITY THERAPEUTICS PRICES UPSIZED IPO AT $18 A SHARE, RAISING ABOUT $200 MILLION
The RNAi drug developer sold 11.1M shares and is expected to begin trading on Nasdaq on Oct. 16 under $CTY, with Goldman Sachs, Jefferies and Stifel among the bookrunners, per the company
顯示更多